The PROG-IMT project is a large, international and cooperative meta-analysis project, based on individual subjects’ data. The key issue is to assess the effective association between the individual IMT progression and future clinical events, like myocardial infarction, stroke or vascular death.
To investigate individual IMT progression as a surrogate for vascular clinical events, and for the interpretation of the results from IMT progression-based clinical trials or pathophysiologic studies, we want to answer the following questions:
(a) Does IMT progression (independently) predict clinical vascular events (MI, stroke, death) in population-based samples, and how can we translate IMT progression in predicted risk?
(b) Does IMT progression (independently) predict clinical vascular events in prevalent disease populations (eg, coronary heart disease, stroke, hypertension, diabetes), and are the risk estimates comparable between different risk groups and between these and the general population?
(c) Do interventions affecting IMT progression quantitatively predict a therapeutic effect on clinical end points?
The three stages of the project:
As the three questions require different types of populations, the project is divided into three consecutive stages:
1. general population samples
2. risk population samples
3. clinical trials in risk groups
The rationale of the project, including the project plan has been published recently (Lorenz et al. 2010). The project is funded by the German Research Foundation (DFG).